A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Abstract Background The purpose of this study was to evaluate both the biodistribution and safety of 64Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel 64Cu-labeled positron emission tomography (PET) tracer for human epidermal growth factor receptor 2 (HER2) in patients wi...

Full description

Bibliographic Details
Main Authors:	Inki Lee, Ilhan Lim, Byung Hyun Byun, Byung Il Kim, Chang Woon Choi, Sang-Keun Woo, Kwang Il Kim, Kyo Chul Lee, Joo Hyun Kang, Min-Ki Seong, Hyun-Ah Kim, Woo Chul Noh, Sang Moo Lim
Format:	Article
Language:	English
Published:	SpringerOpen 2021-01-01
Series:	EJNMMI Research
Subjects:	HER-2 64Cu-NOTA-Trastuzumab Breast cancer Positron emission tomography Computed tomography
Online Access:	https://doi.org/10.1186/s13550-021-00746-1

Similar Items

Comparison of the Effects of DOTA and NOTA Chelators on <sup>64</sup>Cu-Cudotadipep and <sup>64</sup>Cu-Cunotadipep for Prostate Cancer
by: Inki Lee, et al.
Published: (2023-08-01)

Preparation and Preliminary Biodistribution Study of 64Cu-NOTA-NOC
by: ZHAO Hailong;LI Zequang;LUO Tianwei;HUANG Xuhu;WANG Ning;CHEN Mengyi;XU Lin;SHI Xudong;DENG Xuesong;LI Hongyu
Published: (2021-08-01)

Deep Learning-Based Delayed PET Image Synthesis from Corresponding Early Scanned PET for Dosimetry Uptake Estimation
by: Kangsan Kim, et al.
Published: (2023-09-01)

Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma
by: Inki Lee, et al.
Published: (2020-01-01)

Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and 89Zr for Theranostic Application Against HER2‐Expressing Breast Cancers
by: Dr. Joo Hee Jang, et al.
Published: (2019-04-01)

Increasing Reaction Rates of Water-Soluble Porphyrins for <sup>64</sup>Cu Radiopharmaceutical Labeling
by: Mateusz Pęgier, et al.
Published: (2023-03-01)

Neurorestorative Effects of a Novel Fas-Associated Factor 1 Inhibitor in the MPTP Model: An [18F]FE-PE2I Positron Emission Tomography Analysis Study
by: Hyun Soo Park, et al.
Published: (2020-06-01)

Automatic Quantitative Assessment for Diagnostic and Therapeutic Response in Rodent Myocardial Infarct Model
by: Kangsan Kim, et al.
Published: (2024-01-01)

Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
by: Seonhwa Lee, et al.
Published: (2019-02-01)

Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the <sup>64</sup>Cu-Labelling of Immunoconjugates
by: Aurélie Maisonial-Besset, et al.
Published: (2022-12-01)

Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
by: Jae Pil Hwang, et al.
Published: (2016-01-01)

Development of a 64Cu-labeled CD4+ T cell targeting PET tracer: evaluation of CD4 specificity and its potential use in collagen-induced arthritis
by: Anne Skovsbo Clausen, et al.
Published: (2022-09-01)

Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
by: Tae-Hwan Kim, et al.
Published: (2021-03-01)

Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging
by: Hwa Yeon Jeong, et al.
Published: (2024-02-01)

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells
by: Yuna Kim, et al.
Published: (2023-09-01)

Predictive Value of <sup>18</sup>F-Fluorodeoxyglucose Positron-Emission Tomography Metabolic and Volumetric Parameters for Systemic Metastasis in Tonsillar Cancer
by: Jooin Bang, et al.
Published: (2022-12-01)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
by: Zhou Qiong, et al.
Published: (2020-07-01)

Pulmonary actinomycosis mimicking lung cancer on positron emission tomography
by: Hayoung Choi, et al.
Published: (2017-01-01)

Estimation of an Image Biomarker for Distant Recurrence Prediction in NSCLC Using Proliferation-Related Genes
by: Hye Min Ju, et al.
Published: (2023-02-01)

Therapeutic Response Monitoring with <sup>89</sup>Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
by: Minwoo Kang, et al.
Published: (2022-06-01)

Development of new copper-64 labeled rhodamine: a potential PET myocardial perfusion imaging agent
by: Norah AlHokbany, et al.
Published: (2022-07-01)

Efficacy of Positron Emission Tomography/Computed Tomography in Gastric Mucosa-associated Lymphoid Tissue Lymphoma
by: Jin Won Hwang, et al.
Published: (2016-04-01)

Editorial: In-vivo targeting of nuclear DNA with radioactive copper-64 ions
by: Bianca Gutfilen, et al.
Published: (2023-11-01)

More Accurate Differential Properties of LED64 and Midori64
by: Ling Sun, et al.
Published: (2018-09-01)

Tau positron emission tomography in tauopathies: A narrative review
by: Hyunjong Lee, et al.
Published: (2023-03-01)

Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin’s lymphoma
by: Yu Ri Kim, et al.
Published: (2021-03-01)

No Interference of H9 Extract on Trastuzumab Pharmacokinetics in Their Combinations
by: Seung Yon Han, et al.
Published: (2023-11-01)

Focus on the controversial aspects of 64Cu-ATSM in tumoral hypoxia mapping by PET imaging
by: Mathilde eColombié, et al.
Published: (2015-08-01)

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
by: Chung Young Kim, et al.
Published: (2019-08-01)

An ECMA-55 Minimal BASIC Compiler for x86-64 Linux®
by: John Gatewood Ham
Published: (2014-10-01)

Trastuzumab and ECG Changes Dilemma
by: Azin Alizadehasl, et al.
Published: (2023-04-01)

Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology∗
by: Richard M. Steingart, MD, et al.
Published: (2019-09-01)

A Case of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging of Eosinophilic Granulomatosis With Polyangiitis Combined With Non-tuberculous Mycobacterium
by: Juhyung Kim, et al.
Published: (2019-11-01)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
by: Baubek Spanov, et al.
Published: (2022-01-01)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01)

Intermediate commodore 64 /
by: 180879 Grotke, Guy
Published: (1984)

Quantum Neural Network Based Distinguisher on SPECK-32/64
by: Hyunji Kim, et al.
Published: (2023-06-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor Center <sup>18</sup>F-FDG PET Images
by: Jingyu Kim, et al.
Published: (2021-10-01)

In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla
by: Wiesław Guz, et al.
Published: (2024-01-01)